“Novel approaches” needed for MS, claims doctor

[MSUK]

In patients with primary progressive multiple sclerosis (PPMS), Gilenya resulted in similar mean percent brain volume change (PBVC) and per cent change in spinal cord area (PCSCA) vs. placebo, according to data from the INFORMS study... Read More - http://www.ms-uk.org/MSnews